Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia
Open Access
- 5 December 2019
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 134 (23), 2036-2045
- https://doi.org/10.1182/blood.2019000069
Abstract
Key Points Nilotinib demonstrated efficacy and a manageable safety profile in pediatric patients with newly diagnosed and pretreated Ph+ CML-CP.Keywords
This publication has 28 references indexed in Scilit:
- Long‐term results of high‐dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experienceBritish Journal of Haematology, 2015
- Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during pubertyHaematologica, 2012
- Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phaseEuropean Journal of Clinical Pharmacology, 2011
- Distinct Impact of Imatinib on Growth at Prepubertal and Pubertal Ages of Children with Chronic Myeloid LeukemiaThe Journal of Pediatrics, 2011
- Imatinib Is Effective in Children With Previously Untreated Chronic Myelogenous Leukemia in Early Chronic Phase: Results of the French National Phase IV TrialJournal of Clinical Oncology, 2011
- Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up resultsBlood, 2011
- Treatment of Pediatric Chronic Myeloid Leukemia in the Year 2010: Use of Tyrosine Kinase Inhibitors and Stem-Cell TransplantationHematology-American Society Hematology Education Program, 2010
- AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABLBritish Journal of Cancer, 2006
- Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome–positive chronic-phase chronic myeloid leukemia after failure of interferon-αBlood, 2004
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003